Besides the synergistic effect of the BeA and Dox combination, the BSA-(BeA+Dox) DDS diminished to half the expression of EGFR commonly produced in NSCLC by chemotherapeutic agents such as Dox. This evidence concerns the gene EGFR and non-small cell lung carcinoma.